- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- June 02, 2025
- Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- May 31, 2025
- Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- May 30, 2025
- Astellas and Pfizer's XTANDITM (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- May 22, 2025
- Pfizer Enters into Exclusive Licensing Agreement with 3SBio
- May 19, 2025
- Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
- April 29, 2025
- Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- April 26, 2025
- Pfizer Announces 2025 Shareholder Meeting Preliminary Results
- April 24, 2025
- Pfizer Declares Second-Quarter 2025 Dividend
- April 23, 2025
- Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
- April 23, 2025
- ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
- April 16, 2025
- Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
- April 14, 2025
- Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
- April 10, 2025
- European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
- April 01, 2025
- Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
- March 18, 2025
- Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- March 11, 2025
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- February 24, 2025
- Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
- February 13, 2025
- U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- February 12, 2025
- Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- February 10, 2025
- Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
- February 04, 2025
- Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
- February 03, 2025